An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate.

There was significantly increased MPO expression, to approximately 1.5%, in SW1222 tumours 24 h after CA4P treatment but there was large variability in MPO expression between individual CA4P-treated tumours such that the apparent 50% reduction by prior treatment with Y27632 (Figure 5 A and B) was only borderline significant (significant according to Newman–Keuls but not Bonferroni post hoc test).

also in 11,409 other papers